ADC Antibody

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.

Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators (Datopotamab deruxtecan).

Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.

Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targeting tissue factor (TF), utilized in antibody-conjugating drugs for cancer research.

Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to synthesize Gemtuzumab ozogamicin, an antibody coupled compound (ADC) Gemtuzumab is used in the study of acute myeloid leukemia.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Polatuzumab is a monoclonal antibody that targets CD79b and carries chemotherapeutically active molecules.Polatuzumab adheres to CD79b proteins and transports the chemotherapeutically active molecules into cells to kill them.Polatuzumab can be used to synthesize the antibody-compound coupling, Polatuzumab Vedotin.

Iladatuzumab vedotin (DCDS-0780A) is an ADC compound targeting CD79b, conjugated with the cytotoxic drug MMAE through a cleavable dipeptide linker mc-val-cit-PABC, used in the study of non-Hodgkin lymphoma.

Clivatuzumab MMAE is an ADC consisting of a humanized monoclonal antibody against MUC1 (mucin) and the anti-mitotic cytotoxin MMAE for pancreatic cancer.

Rosopatamab MMAE (HUJ-591 MMAE) is an ADC consisting of a PSMA-directed antibody (humanized IgG1 monoclonal antibody against PSMA and monomethylauristatin E (MMAE) for prostate cancer research.

Naratuximab (Anti-TSPAN26 CD37 Reference Antibody) is a humanized monoclonal antibody against CD37 that can be used to synthesize the ADC compound Naratuximab emtansine.

Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17). Belantamab is a naked antibody to Belantamab mafodotin and can be used to synthesize antibody-active molecule conjugates (Belantamab mafodotin).

Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).

Raludotatug deruxtecan (DS-6000) is an ADC compound targeting CDH6 with anti-cancer activity, used in the study of ovarian cancer.

Tamrintamab (SC-003 mAb) is an antibody targeting dipeptidase 3 (DPEP3), a potential cytotoxic agent for ovarian cancer research.

Disitamab Vedotin (RC48-0) is a humanized monoclonal antibody that targets HER2 and can be utilized in creating antibody-drug conjugates (ADCs), specifically referred to as Disitamab Vedotin [1].

Cantuzumab is a monoclonal antibody targeting the CanAg antigen with anti-tumor activity, used in the synthesis of the ADC compound cantuzumab mertansine.

Lonigutamab (hz208F2-4) is a humanized monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) for the study of thyroid eye disease.

Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. This naked antibody can be used to synthesize antibody-active molecule conjugators [Inotuzumab ozogamicin] and to study acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Glembatumumab, CY3 labeled is a humanized antibody targeting the extracellular domain of GPNMB, with potential antitumor activity, used in studies of triple-negative breast cancer.

Lorvotuzumab (Anti-NCAM1 CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.